Clinical Characteristics of Early-Onset and Late-Onset Leigh Syndrome

Chan-Mi Hong 1, Ji-Hoon Na 1, Soyoung Park 2 and Young-Mock Lee 1*

1 Departments of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea, 2 Department of Pediatrics, Soon Chun Hyang University Hospital and College of Medicine, Soonchunhyang University, Bucheon-si, South Korea

Background: Leigh syndrome (LS) is the most common pediatric mitochondrial diseases caused by MRC defect. LS patients typically have onset age before 2 years old and have various clinical features. The purpose of this study was to evaluate the various characteristics between the group that were early onset and late onset patients.

Methods: The medical records of this study used records between 2006 and 2017 (N = 110). Clinical characteristics, diagnostic evaluations, and neuro image studying of LS were reviewed in our study. We statistically analyzed data from patients diagnosed with LS at our hospital by using subgroup analysis was performed to divide patients according to the onset age.

Results: Among the patients, 89 patients (80.9%) had the onset age before 2 years old, and 21 patients (19.1%) had onset age after 2 years old. In subgroup analysis first clinical presentation age, diagnosis age and several onset symptoms in the clinical characteristics were statistically significant. Early onset age group showed delayed development and late onset age group showed motor weakness and ataxia. However, Diagnostics evaluation and MRI findings showed no significant differences. The clinical status monitored during the last visit showed statistically significant differences in the clinical severity. In the early onset age group clinical status was more severe than late onset age group.

Conclusions: Although the onset of Leigh syndrome is known to be under 2 years, there are many late onset cases were existed more than expected. Early onset LS patients have poor prognosis compare with late onset LS patients. Therefore, the specific phenotype according to the age of onset should be well-observed. Onset of LS is important in predicting clinical severity or prognosis, and it is necessary to provide individualized treatment or follow-up protocols for each patient.

Keywords: Leigh syndrome, late onset, early onset, prognosis, pediatric, mitochondrial disease

INTRODUCTION

Leigh syndrome (LS) is an early-onset progressive neurodegenerative disease representing the most common pediatric clinical presentation of mitochondrial disease (1–3). LS was named after Denis Leigh, the first man to describe this rare neuropathology of infants and young children, which caused death in the affected patients. LS is known to affect about 1 in 40,000 births (4–7).
Although LS is associated with considerable clinical and genetic heterogeneity, the characteristic neuropathological features are remarkably consistent. Patients with LS most commonly manifest a progressive decline of central nervous system function due to focal, necrotizing lesions of the basal ganglia, diencephalon, cerebellum, or brainstem (5). The clinical hallmarks of LS include psychomotor delay or regression, weakness, hypotonia, truncal ataxia, intention tremor, and lactosidosis of the blood, cerebrospinal fluid (CSF), or urine (6).

The clinical manifestations of LS usually persist for up to 2 years after the initial development. LS patients are typically described to have the onset time before 2 years of age along with various clinical features. The disease course is associated with episodic neurodegeneration, often terminating with death at the age of 3 years (4, 6, 7, 9–11). Although adult-onset LS has been reported, it is very rare (12, 13). The purpose of this study was to evaluate the clinical features, and laboratory and image findings of LS by comparing these findings in patients with early-onset and late-onset LS.

MATERIALS AND METHODS

Patients Group

This study was a retrospective analysis of patients diagnosed with LS and followed up at Gangnam Severance Hospital from January 2006 to January 2017. Patients who fulfilled the following criteria: (1) progressive neurological disease with motor and intellectual developmental delay; (2) signs and symptoms of brainstem and/or basal ganglia disease; (3) raised lactate levels in the blood and/or CSF; and (4) one or more of the following: (a) characteristic features of LS on neuroradioimaging [symmetrical hypodensities in the basal ganglia on computed tomography (CT) or hyperintense lesions on T2-weighted magnetic resonance imaging (MRI)], (b) typical neuropathological changes postmortem, or (c) typical neuropathology in a similarly affected sibling (14) were included.

The Institutional Review Board of Gangnam Severance Hospital in Seoul, Korea approved all our procedures. Informed consent was obtained from the parents, and all methods were performed in accordance with relevant guidelines and ethics board regulations.

Data Collection Regarding Clinical Characteristics, Diagnostic Evaluation, Neuroimaging and Clinical Status at the Last Visit

Clinical data on the age at first clinical presentation, age at diagnosis, period from the first symptoms to the last visit, birth history, family history, nature of the first symptom, and organ involvement were collected.

Laboratory test results, including serum lactate acid levels and creatine kinase levels, were also obtained. The degree of serum lactate acidosis was defined as mild, moderate, or severe if the increase was <2, <3, or >3-fold higher than the normal reference values, respectively. Biochemical enzyme assay of the muscle tissue was also performed to evaluate the mitochondrial respiratory chain (MRC) complex enzyme activity. MRC complex enzyme defect was defined as a residual enzyme activity of <10% the reference value. Muscle biopsies were performed on the quadriceps muscle, and histologic examinations were performed using a light microscope and an electron microscope. Specific findings for mitochondrial diseases under a light microscope were defined as the presence of ragged red fibers (RRF) or abnormal staining. Abnormal mitochondrial morphology was defined under the electron microscope as pleoconia and megaconia. Data from genetic test of nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) was collected. Brain MRI studies were also performed. The images used in this study were taken at the time of diagnosis of LS.

The clinical severity of LS in the patients was defined as: normal, ambulatory, and independent for daily activities; mild, ambulatory, or independent for daily activities; moderate, wheelchair-bound, or partially dependent for daily activities; and severe, bedridden, totally dependent for daily activities, or dead. At the last visit, data on whether they had undergone tracheostomy, home vent use, O2 dependence, and enteral tube feeding were also collected.

Subgroup Analysis by Age at Onset

A total of 110 patients were recruited in this study. Patients were divided into two groups based on their age at LS onset. Age at LS onset was divided into onset age of before the second year of life (late onset group) and onset age of before the second year of life (early-onset group). Clinical features, laboratory findings, and image findings were compared between the two groups.

Statistical Analysis

All analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 22.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were used, including the median and range. Differences between subgroups were evaluated using the Mann-Whitney U-test (Wilcoxon rank sum test) and Fisher’s exact test. P-values of <0.05 were considered statistically significant.

RESULTS

Distribution of LS by Age at Onset

A total of 110 patients were diagnosed with LS. Among the patients, 89 patients (80.9%) had an onset age of before 2 years old, and 21 patients (19.1%) had an onset age of after 2 years old. In 89 patients with a typical onset age of <2 years old, 17 patients (15.5%) were between 1 and 2 years old and 72 patients (65.5%) were under 1 year of age.

Patient Characteristics and Clinical Features

Of the 110 patients who were diagnosed with LS, 51 (46.4%) patients were male and 59 (53.6%) were female. The median age at the first clinical presentation was 9 months (range 0–186 months). The median age at the diagnosis of LS was 25 months (range 3–244 months). The time interval between the first clinical presentation and the diagnosis of Leigh syndrome was 13 months.
onset age of under 2 years, and the age at first clinical presentation
and the age at LS diagnosis were statistically significant ($P < 0.05$).

The presenting symptom at disease onset varied, with delayed
development (55 patients, 45.5%) as the most common, followed
by seizures (24 patients, 21.6%), motor weakness (11 patients,
9.5%), drowsiness (7 patients, 6.3%), ataxia (5 patients, 4.5%),
muscle atrophy (3 patients, 2.7%), and visual disturbance (2
patients, 1.8%). There were three significant differences in
presenting symptoms between the early-onset and late-onset
groups. Delayed development was significantly higher in the
early-onset group than in the late-onset group. Motor weakness
and ataxia were significantly higher in the late-onset group than
in the early-onset group. Among those 24 patients who showed
seizure as the presenting symptom at disease onset, we found that
11 patients (45.8%) had a focal seizure locus while 8 (33.3%) had
generalized seizure semiology. Complex partial seizure was the
most common type of focal seizure observed. As for generalized
seizure types, myoclonic seizure, tonic seizure, atonic seizure, and
tonic-clinic seizure were observed with relatively even prevalence
among patients. In addition, two patients showed partial seizure
with secondary generalization and three patients had unclassified
epileptic seizures. There was no significant difference in seizure
types between the early-onset and late-onset groups.

All the patients experienced involvement of the central
nervous system, followed by the muscular systems,
gastrointestinal and respiratory systems, and several organs.
Among the organ involvements, involvement of the muscular
systems, such as myopathy, creatine kinase level elevation, and
positive muscle biopsy findings, was significantly higher in the
late-onset group (Table 1).

**Diagnostic Evaluation of Leigh Syndrome**

The median serum lactate level at the time of diagnosis was
2.6 (range 0.9–20.7), and at the time of the last visit, it was 2.0
(range 0.6–14.0). Serum lactic acid level was increased in 64
patients (58.7%). Serum levels of lactic acid were found to be
mildly increased, moderately increased, and severely increased
in 26.6, 24.8, and 7.3% of patients, respectively. In most cases,
serum creatine kinase levels were normal both at the time of the
diagnosis and at the last visit.

Biochemical evaluation of MRC complex enzyme function
in the muscle tissue of 92 patients (no biochemical evaluation
results were found for 18 patients) showed defects in MRC
complex I and MRC complex IV in 53 patients (57.6%) and
34 patients (37.0%), respectively. Muscle biopsy, performed for
100 of the 110 patients, showed abnormal changes under a light
microscope in 25 patients (25%), including nonspecific findings
(3 patients), specific mitochondrial disease (22 patients), such
as RRF and abnormal staining. Abnormal findings under an
electron microscope were observed in 72 patients (72%); these
included pleoconia (37 patients) and megaconia (35 patients).

There was no significant difference between the subgroups
in lactic acidosis and elevation of serum creatine kinase
levels. In addition, no significant difference in MRC complex
enzyme assay and muscle biopsy findings was observed in the
subgroup analysis (Table 2).

In our study, genetic test of whole mtDNA and nDNA
was not performed in every patient. Out of 110 patients
with Leigh syndrome who met the clinical criteria, three
patients showed nDNA mutation and all had SURF1 gene
mutation. The mtDNA mutation was confirmed in 22 patients
(Supplementary Tables 1, 2).

**MRI Findings in Leigh Syndrome**

MRI of the brain revealed several abnormal findings in the
patients, including atrophy or abnormal signals in different areas
of the brain. Basal ganglia (104 patients, 94.5%) was the most
common abnormal MRI findings, followed by cerebral atrophy
(64 patients, 58.2%), and brainstem (45 patients, 40.9%), and
white matter signal abnormality (42 patients, 38.2%). There
was no significant difference between the subgroup in MRI
findings (Table 3).

**Clinical Status at Last Visit**

At the last outpatient clinic visit, 9 patients (8.2%) showed a
mild clinical severity (ambulatory and/or independent for daily
activities), 32 patients (29.1%) showed moderate clinical severity
(wheelchair-bound and/or partially dependent for daily activities,
able to express and understand direction), 58 patients (52.7%)
showed critical clinical severity (bedridden, total dependence
for daily activities), and the other patients were dead (11
patients, 10%). In addition, 27 patients underwent tracheostomy,
25 patients utilized home ventilator, 23 patients showed O$_2$
dependence, and 38 patients were on enteral tube feeding.

By dividing the patients into subgroups according to onset
age, we found differences in clinical severity at the last visit to
be statistically significant. The clinical status of the early-onset
group was more severe (59.6%) than that of the late-onset group.
Therefore, the early-onset group had a poor prognosis compared
to the late-onset group. There was no significant difference
between the subgroups in previous tracheostomy, home vent use,
O$_2$ dependence, and enteral tube feedings (Table 4).

**DISCUSSION**

LS is traditionally considered to be a disease of infancy and early
childhood that occurs before the age of 2 years (4, 15–17). More
than 50% of cases are observed in patients within one year of
age, usually six months old. Late-onset LS is rare worldwide (18).
Karin et al. described 25 patients with LS, and all 25 patients
had age onset younger than 2 years (16). Yang et al. described
65 patients with LS, and the age of LS onset in 59 patients was
<1 year (19). In our study, the onset age ranged from <1 to 187
months. There are many criteria to classify age of onset, and clear
criteria have not yet been established. Therefore, we divided early
TABLE 1 | Clinical characteristics of Leigh syndrome.

|                                | Total                      | Subgroup by age at onset | P-value |
|--------------------------------|----------------------------|--------------------------|---------|
|                                | Age ≤ 2yr (n = 89)         | Age > 2yr (n = 21)       |         |
| **Sex**                        |                            |                          | 0.228   |
| Male                           | 51 (46.4%)                 | 44 (49.4%)               | 7 (33.3%) |
| Female                         | 59 (53.6%)                 | 45 (50.6%)               | 4,514 (66.7%) |
| **Age at the first clinical presentation (month)** | 9 (0 – 186) | 7 (0–24) | 44 (25–186) | <0.001 |
| **Age at the diagnosis of LS (month)** | 25 (3 – 244) | 21 (3–186) | 60 (25–244) | <0.001 |
| **The interval between the first clinical presentation and diagnosis of LS (month)** | 13 (0 – 173) | 13 (0–153) | 12 (0–173) | 0.698 |
| **The duration from LS diagnosis to the last clinic visit (month)** | 109 (4 – 290) | 109 (4–281) | 117 (22–290) | 0.822 |
| **The duration of follow-up from symptom onset to the last clinic visit (month)** | 83 (0 – 221) | 82 (0–221) | 83 (0–147) | 0.976 |
| **Birth history**              |                            |                          |         |
| Prematurity                    | 4 (3.6%)                   | 4 (4.5%)                 | 0 (0.0%) | 0.423 |
| Intrauterine growth retardation| 5 (4.5%)                   | 5 (5.6%)                 | 0 (0.0%) | 0.126 |
| Perinatal asphyxia             | 7 (6.4%)                   | 4 (4.5%)                 | 3 (14.3%) | 0.241 |
| Neonatal intensive care unit history | 13 (11.8%) | 12 (13.5%) | 1 (4.8%) | 0.339 |
| **Family history**             |                            |                          |         |
| Mitochondrial disease history  | 16 (14.5%)                 | 11 (12.4%)               | 5 (23.8%) | 0.406 |
| Non-specific neurological disease history | 13 (11.8%) | 9 (10.1%) | 4 (19.0%) | 0.359 |
| **Presenting symptom at disease onset** | 3 (2.7%) | 2 (2.2%) | 1 (4.8%) | 0.191 |
| Delayed development            | 55 (49.5%)                 | 50 (56.2%)               | 5 (23.8%) | 0.008 |
| Seizure                        | 24 (21.6%)                 | 20 (22.5%)               | 4 (19.0%) | 0.495 |
| Motor weakness                 | 11 (9.9%)                  | 6 (6.7%)                 | 5 (23.8%) | 0.019 |
| Drowsiness                     | 7 (6.3%)                   | 5 (5.6%)                 | 2 (9.5%) | 0.400 |
| Ataxia                         | 5 (4.5%)                   | 2 (2.2%)                 | 3 (14.3%) | 0.047 |
| Muscle atrophy                 | 3 (2.7%)                   | 3 (3.4%)                 | 0 (0.0%) | 0.526 |
| Visual disturbance             | 2 (1.8%)                   | 1 (1.1%)                 | 1 (4.8%) | 0.347 |
| Ear disorder                   | 1 (0.9%)                   | 1 (1.1%)                 | 0 (0.0%) | 0.809 |
| Behavior change                | 1 (0.9%)                   | 0 (0.0%)                 | 1 (4.8%) | 0.191 |
| Ptosis                         | 1 (0.9%)                   | 1 (1.1%)                 | 0 (0.0%) | 0.809 |
| **Organ involvement**          |                            |                          |         |
| Central nervous system         | 110 (100%)                 | 89 (100.0%)              | 21 (100.0%) | – |
| Muscular                       | 52 (47.3%)                 | 38 (42.7%)               | 14 (66.7%) | 0.048 |
| Gastrointestinal               | 41 (37.3%)                 | 35 (39.3%)               | 6 (28.6%) | 0.359 |
| Respiratory                    | 33 (30.0%)                 | 29 (32.6%)               | 4 (19.0%) | 0.171 |
| Ophthalmic                     | 17 (15.5%)                 | 15 (16.9%)               | 2 (9.5%) | 0.323 |
| Cardiologic                    | 9 (8.2%)                   | 9 (10.1%)                | 0 (0.0%) | 0.137 |
| Renal                          | 8 (7.3%)                   | 8 (9.0%)                 | 0 (0.0%) | 0.172 |
| Auditory                       | 6 (5.5%)                   | 4 (4.5%)                 | 2 (9.5%) | 0.322 |
| Hematologic                    | 1 (0.9%)                   | 0 (0.0%)                 | 0 (0.0%) | – |
| Endocrinologic                 | 1 (0.9%)                   | 1 (1.1%)                 | 0 (0.0%) | 0.809 |

*Continuous variables are described by medians and ranges.
Other variables are described by number of patients and percentage (%) in each group.

onset and late onset based on age of 2 years. Under 2 years old age onset were dominant in 80.9%.

According to previous reports, typical signs and symptoms may appear in late-onset LS (20). In late-onset Leigh syndrome, there was intellectual decline and vertical gaze paralysis, headache, memory loss, and visual hallucinations (21, 22). They were based on a small number of case reports. Generally, Leigh syndrome in adulthood is rare (20). Our results showed that delayed development, motor weakness, and ataxia among the presenting symptoms at disease onset were statistically significant. However, the time interval from the first clinical presentation to the diagnosis of LS, follow-up duration, birth history, family history, and organ involvement were not statistically significant. Therefore, Leigh syndrome should be considered when symptoms related to gross motor function such as delayed development, motor weakness, and ataxia are observed. In particular, these symptoms can be classified according to the age of onset. There is a frequency of difference
**TABLE 2 | Diagnostic evaluation of Leigh syndrome.**

|                     | Total | Subgroup by age at onset | P-value |
|---------------------|-------|--------------------------|---------|
|                     |       | Age ≤ 2yr (n = 89)       | Age > 2yr (n = 21) |
| **Lactate (mmol/L)**|       |                         |         |
| *At the time of diagnosis* | 2.6   | 0.9–20.7                 | 2.4     | 1.2–7.0 | 0.563 |
| *Last visit*        | 2.0   | 0.6–14.0                 | 1.9     | 0.6–4.3 | 0.066 |
| **Lactate/pyruvate ratio**|       |                         |         |
| *At the time of diagnosis* | 16.8  | 4.8–260.0                | 17.0    | 4.8–260.0 | 15.7 | 7.1–40.0 | 0.396 |
| *Last visit*        | 16.1  | 4.8–176.9                | 16.8    | 4.8–88.6 | 15.7 | 5.0–176.9 | 0.142 |
| **Lactic acidosis (n = 109)**|       |                         |         |
| Normal              | 45    | 41.3 (%)                 | 36      | 40.4 (%) | 9   | 45.0 (%) |         |
| Mild increased (>2-fold) | 29    | 26.6 (%)                 | 22      | 24.7 (%) | 7   | 35.0 (%) | 0.193 |
| Moderate increased (>3-fold) | 27    | 24.8 (%)                 | 24      | 27.0 (%) | 3   | 15.0 (%) |         |
| Severe increased (>4-fold) | 8     | 7.3 (%)                  | 7       | 7.9 (%) | 1   | 5.0 (%) |         |
| **Creatine kinase (mmol/L)**|       |                         |         |
| *At the time of diagnosis* | 101   | 15 – 1,257              | 99      | 15–1,257 | 109 | 22–409 | 0.948 |
| Normal              | 75    | 68.2 (%)                 | 58      | 65.2 (%) | 56  | 62.9 (%) |         |
| Mild increased (<2-fold) | 29    | 26.4 (%)                 | 26      | 29.2 (%) | 25  | 28.1 (%) | 0.996 |
| Severe increased (>2-fold) | 6     | 5.5 (%)                  | 5       | 5.6 (%) | 8   | 9.0 (%) |         |
| *Last visit*        | 113   | 7–873 (%)                | 117     | 7–873 | 105 | 27–595 | 0.550 |
| Normal              | 69    | 62.7 (%)                 | 17      | 81.0 (%) | 13  | 61.9 (%) |         |
| Mild increased (<2-fold) | 31    | 28.2 (%)                 | 3       | 14.3 (%) | 6   | 28.6 (%) | 0.353 |
| Severe increased (>2-fold) | 10    | 9.1 (%)                  | 1       | 4.8 (%) | 2   | 9.5 (%) |         |
| **Plasma amino acid (n = 88)**|       |                         |         |
| *Alanine*           | 389   | 102–1,028                | 390     | 158–1,028 | 378 | 102–652 | 0.303 |
| Normal              | 52    | 59.1 (%)                 | 41      | 57.7 (%) | 11  | 64.7 (%) |         |
| Mild increased (>2-fold) | 31    | 35.2 (%)                 | 25      | 35.2 (%) | 6   | 35.3 (%) | 0.721 |
| Severe increased (>4-fold) | 5     | 5.7 (%)                  | 5       | 7.0 (%) | 0   | 0.0 (%) |         |
| *Glycine*           | 213   | 98–8,010                 | 208     | 108–8,010 | 217 | 98–355 | 0.763 |
| Normal              | 87    | 97.8 (%)                 | 70      | 97.2 (%) | 17  | 100.0 (%) |         |
| Abnormal (>2-fold)  | 2     | 2.2 (%)                  | 2       | 2.8 (%) | 0   | 0.0 (%) | 0.785 |
| *Proline*           | 173   | 0–518                    | 176     | 0–518 | 133 | 0–232 | 0.021 |
| Normal              | 82    | 92.1 (%)                 | 66      | 90.3 (%) | 17  | 100.0 (%) |         |
| Abnormal (>2-fold)  | 7     | 7.9 (%)                  | 7       | 9.7 (%) | 0   | 0.0 (%) | 0.408 |
| *Threonine*         | 116   | 38–762                   | 117     | 38–762 | 101 | 43–177 | 0.031 |
| Normal              | 94    | 85.5 (%)                 | 78      | 92.9 (%) | 16  | 94.1 (%) | 0.128 |
| *Abnormal (>2-fold) | 7     | 6.4 (%)                  | 6       | 7.1 (%) | 1   | 5.9 (%) |         |
| **Urine organic acid (n = 71)**|       |                         |         |
| Abnormal finding    | 36    | 50.7 (%)                 | 28      | 50 (%)  | 8   | 53.3 (%) | 0.819 |
| MRC complex enzyme assay (n = 92) |       |                         |         |
| MRC complex I defect | 53    | 57.6 (%)                 | 42      | 47.2 (%) | 11  | 64.7 (%) | 0.888 |
| MRC complex IV defect | 34    | 37.0 (%)                 | 29      | 32.6 (%) | 5   | 29.4 (%) |         |
| **Muscle biopsy obtained**|       |                         |         |
| Light microscopic changes (+) |       |                         |         |
| Specific findings for mitochondrial diseases | 22    | 22 (%)                   | 15      | 18.8 (%) | 7   | 35.0 (%) |         |
| Non-specific findings | 3     | 3 (%)                    | 3       | 3.8 (%) | 0   | 0.0 (%) |         |
| Electron microscopic changes (+) |       |                         |         |
| Pleocenia           | 37    | 37 (%)                   | 26      | 32.5 (%) | 11  | 55.0 (%) | 0.123 |
| Megaconia           | 35    | 35 (%)                   | 25      | 31.3 (%) | 10  | 50.0 (%) | 0.207 |

*Continuous variables are described by medians and ranges. Other variables are described by number of patients and percentage (%) in each group.*
between the specific symptoms in early onset and late onset patients. Delayed development is important in cases of early age of onset, and motor weakness or ataxia is important in cases of late age of onset. Consequently, mitochondrial disease should be suspected if the initial symptoms such as delayed development, motor weakness, and ataxia and regression are
detected. Seizure and epilepsy in children with early-onset mitochondrial disease may be a presenting or a prominent symptom in a multisystemic clinical presentation. However, a higher prevalence of Leigh syndrome was detected in non-epileptic patients (23, 24). Though seizures took the place of the second most common presenting symptom at disease onset in our study, there was no case of severe condition as status epilepticus. The most frequent causes of mitochondrial status epilepticus are known as mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) and myoclonus epilepsy with ragged-red fibers (MERRF) (25).

LS is typically characterized by the involvement of the brainstem and/or basal ganglia (4, 26). Other areas of frequent involvement include the thalamus, cerebellum, and spinal cord (7, 14). Similar to previous studies, brainstem, basal ganglia, and thalamus involvement were more common in our results, with basal ganglia involvement being the most common. There was no significant difference between MRI findings according to onset age. Therefore, it is clinically meaningful to compare the interval changes in neuroimaging by individual follow up rather than MRI findings according to onset age. Although the consensus on when to repeat brain MRI in LS has not reached a definite conclusion yet, it is important to follow up MRI findings at regular intervals to compare changes.

The disease course is associated with episodic neurodegeneration, often ending with death until the age of 5 years (27). However, according to our results, the median time from the first symptom onset to the last visit was 83 months, which is longer than what was observed in previous studies. No causative treatment is available for Leigh disease because no treatment can reverse the sustained damage. Thus, the goal of each treatment are to reduce the expected deterioration rate and to alleviate symptoms such as respiratory disturbances and tube feeding. The reason for the prolongation of patient's survival period to 5 years or more is considered to be due to multidisciplinary treatment and supportive care, including serial monitoring and the use of various medication at LS diagnosis. The type of medication used supplements RC components like coenzyme Q, administers artificial electron acceptors like vitamin C and K, and administers metabolites and cofactors like carnitine, thiamin, and riboflavin (28). The clinical severity of LS in the early-onset group was worse than in the late onset group, and in the early-onset group, the proportion of patients with critical clinical severity or those who died was 70.8%, whereas in the late-onset group, 71.4% of patients had mild or moderate clinical severity. A difference in prognosis was shown according to onset age. Although there are reports of both early and late-onset LS, there is no comparative study of their prognosis. Therefore, it is necessary to compare their prognosis according to the age at onset.

Our study is a retrospective study with limited genetic diagnosis. A study conducted using retrospective design generally includes patients recruited over a long period making it practically impossible to perform genetic assessment in all patients and under the same condition. In our study, genetic tests for whole nDNA and mtDNA were not performed in all patients. Therefore, the number of patients with a confirmed mutation was too small to make statistically meaningful analysis. A study based on a large sample with full genetic assessment would be very helpful. Even a smaller cohort with genetic confirmation could be quite significant. However, the rarity of the disease makes it hard to find a study population big enough to provide generalized interpretations. That is also the reason for why studies on rare diseases are scarce when compared with those on common diseases. Despite the limitation of genetic diagnosis, standards of clinical diagnosis criteria, biochemical assay, and muscle pathology were applied very strictly in this study to make definite diagnosis. This was a large-scale study involving more than 100 patients in a single institution that meets previously established diagnostic criteria. Because LS is a rare disease, performing a prospective study has limitations because only a few cases will be available for research. However, we noted that early-onset and late-onset LS are similar in clinical phenotype and MRI finding, but their prognosis is quite different. In this study, we analyzed clinical phenotypes according to onset age. However, long-term studies involving a larger patient cohort with evaluation of the genotype of patients in each group could provide further prediction of the prognosis in LS. Individualized treatment is possible if we recognize the differences according to the onset age of LS. Therefore, the onset age of LS will ultimately be helpful for personalized treatment.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/supplementary material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of Gangnam Severance Hospital. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

Y-ML conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed and revised the manuscript. C-MH, J-HN, and SP designed the data collection instruments, collected data, and carried out the initial analyses. C-MH drafted the initial manuscript and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for the content of the work.

FUNDING

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: 2018-31-0425/H118C1166020018 & 2018-31-1061/H118C1166020019).
ACKNOWLEDGMENTS

The authors are grateful to all staff members, doctors, and statistical consultants who were involved in this study.

REFERENCES

1. Darin N, Oldfors A, Moslemi AR, Holme E, Tullinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. (2001) 49:377–83. doi: 10.1002/ana.75
2. Munaro M, Tiranti V, Sandonà D, Lamantia E, Uziel G, Bisson R, et al. A single cell complementation class is common to several cases of cytochrome c oxidase-defective Leigh’s syndrome. Hum Mol Genet. (1997) 6:221–8. doi: 10.1093/hmg/6.2.221
3. Piao YS, Tang GC, Yang H, Lu DH. Clinico-neuropathological study of a Chinese case of familial adult Leigh syndrome. Neuropathology. (2006) 26:218–21. doi: 10.1111/j.1440-1789.2006.00686.x
4. Rahman S, Blok RB, Dahl HH, Dansky DM, Kirby DM, Chow CW, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol. (1996) 39:343–51.
5. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry. (1951) 14:216–21.
6. van Erven PM, Cillesen JP, Eekhoff EM, Gabreljes FJ, Doesburg WH, Lemmens WA, et al. Leigh syndrome, a mitochondrial encephaloencephalopathy. A review of the literature. Clin Neurol Neurosurg. (1987) 89:217–30.
7. Montpetit VJ, Andermann F, Carpenter S, Fawcett JS, Zborowska-Sluis D, Giberson HR. Subacute necrotizing encephalomyelopathy. A review and a study of two families. Brain. (1971) 94:1–30.
8. Cooper MP, Qu L, Rohas LM, Lin J, Yang W, Erdjument-Bromage H, et al. Defects in energy homeostasis in Leigh syndrome French Canadian variant through PGC-1alpha/LRP130 complex. Genes Dev. (2006) 20:2996–3009. doi: 10.1101/gad.1483906
9. Ma YY, Wu TF, Liu YP, Wang Q, Song JQ, Li XY, et al. Genetic and biochemical findings in Chinese children with Leigh syndrome. J Clin Neurosci. (2013) 20:1591–4. doi: 10.1016/j.jocn.2013.03.034
10. Campbell IC, Durcan MJ, Cohen RM, Pickar D, Chugani D, Murphy DL. Chronic choreiform and pargyline increase apomorphine-induced stereotypy in the rat. Pharmacol Biochem Behav. (1985) 23:921–5. doi: 10.1016/0091-3057(85)90093-0
11. Sofou K, De Coo IE, Isohanni P, Ostergaard E, Naess K, De Meulier L, et al. A multicenter study on Leigh syndrome: disease course and predictors of survival. Orphanet J Rare Dis. (2014) 9:52. doi: 10.1186/1750-1172-9-52
12. Nagashima T, Morisaki M, Katayama K, Nunomura M, Nishiura H, Hiraga H, et al. Adult Leigh syndrome with mitochondrial DNA mutation at 8993. Acta Neuropathol. (1999) 97:416–22. doi: 10.1007/s0040100105007
13. Chalmers RM, Lamont PJ, Nelson I, Ellison DW, Thomas NH, Harding AE, et al. A mitochondrial DNA tRNA (Val) point mutation associated with adult-onset Leigh syndrome. Neurology. (1997) 49:589–92. doi: 10.1212/WNL.49.2.589
14. Cavanagh JB, Harding BN. Pathogenic factors underlying the lesions in Leigh’s disease. Tissue responses to cellular energy deprivation and their clinico-pathological consequences. Brain. (1994) 117:1357–76. doi: 10.1093/brain/117.6.1357
15. Lee HF, Tsai CR, Chi CS, Lee HJ, Chen CC. Leigh syndrome: clinical and neuroimaging follow-up. Pediatr Neurol. (2009) 40:88–93. doi: 10.1016/j.pediatrneurol.2008.09.020
16. Naess K, Freyer C, Bruhn H, Wibom R, Malm G, Nennesmo I, et al. MitDNA mutations are a common cause of severe disease phenotypes in children with Leigh syndrome. Biochim Biophys Acta. (2009) 1787:484–90. doi: 10.1016/j.bbappbio.2008.11.014
17. Ostergaard E, Hansen FJ, Sorensen N, Duno M, Vissing J, Larsen PI, et al. Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SLCo2 mutations. Brain. (2007) 130:853–61. doi: 10.1093/brain/awl383
18. Sakushima K, Tsuji-Akimoto S, Niino M, Saitoh S, Yabe I, Sasaki H. Adult Leigh disease without failure to thrive. Neurologist. (2011) 17:222–7. doi: 10.1097/NRL.0b013e318217357a
19. Yang YL, Sun F, Zhang Y, Qian N, Yuan Y, Wang ZX, et al. Clinical and laboratory survey of 65 Chinese patients with Leigh syndrome. Chin Med J. (2006) 119:373–7. doi: 10.1097/00029330-20060301-00004
20. Baetling E, Rodenburg RJ, Schaper J, Smeitink JA, Koopman WJH, Mayatepek E, et al. A guide to diagnosis and treatment of Leigh syndrome. J Neurol Neurosurg Psychiatry. (2014) 85:257–65. doi: 10.1136/jnnp-2012-304426
21. Mckelvie P, Infeld B, Marotta R, Chin J, Thorburn D, Collins S. Late-adult onset Leigh syndrome. J Clin Neurosci. (2012) 19:195–202. doi: 10.1016/j.jocn.2011.09.009
22. Gray F, Louarn F, Gherrardi R, Eizenbaum JE, Marsault C. Adult form of Leigh’s disease: a clinic pathological case with CT scan examination. J Neurol Neurosurg Psychiatry. (1984) 47:1211–5. doi: 10.1136/jnnp.47.11.1211
23. Matricardi S, Canafoglia L, Ardissone A, Moroni I, Ragona F, Ghetti D, et al. Epileptic phenotypes in children with early-onset mitochondrial diseases. Neurologist. (2019) 14:184–93. doi: 10.1111/ane.13130
24. Lee S, Na JH, Lee YM. Epilepsy in Leigh syndrome with mitochondrial DNA mutations. Front Neurol. (2019) 10:496. doi: 10.3389/fneur.2019.00496
25. Rahman S. Mitochondrial diseases and status epilepticus. Epilepsia. (2018) 59(Suppl 2):70–7. doi: 10.1111/epi.14485
26. Mascalchi M, Montomoli M, Guerrii R. Neuroimaging in mitochondrial disorders. Essays Biochem. (2018) 62:409–21. doi: 10.1042/EBC20170109
27. Bénit P, Slama A, Cartault F, Giurgea I, Chretien D, Lebon S, et al. Mutant NDUF53 subunit of mitochondrial complex I causes Leigh syndrome. J Med Genet. (2004) 41:14–7. doi: 10.1136/jmg.2003.014316
28. Finsterer J. Mitochondriopathies. Eur J Neurol. (2004) 11:163–86. doi: 10.1046/j.1351-5103.2003.00728.x

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.00267/full#supplementary-material

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hong, Na, Park and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.